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Abstract
Pain is one of the feared effects of advancing cancer and can affect a vast majority of head and neck cancer (HNC) patients. HNC's
have a devastating impact on patient's lives as both disease and treatment can affect the ability to speak, swallow and breathe due to
involvement of the aerodigestive tract. The etiology of pain in this subgroup of patients could be as a result of direct tumor progression,
nerve root compression or as a result of the treatment modalities including surgery radiotherapy and chemotherapy. Pain experienced
could be nociceptive or neuropathic. A thorough initial and ongoing assessment of the patient is essential for diagnosis and planning the
treatment bearing in mind its modification during treatment. Treatment involves a comprehensive approach which is centred around
systematic pharmacotherapy, and supplemented by a range of therapeutic interventions and physical and behavioral approaches. In
this article we discuss the incidence, etiology, assessment and treatment of this challenging problem using current modalities.
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ETIOLOGY OF PAIN IN HNC
Most patients with advanced HNC have more than one cause
of pain. Pain may be due to the cancer itself, effects of the
treatments (surgery, radiotherapy or chemotherapy) other
debilitating conditions or pain unrelated to the cancer.8
Although the physical burden of cancer pain is devastating
it is almost always accompanied by emotional, spiritual,
financial and social stresses. Therefore a multifaceted
approach towards pain management is essential.
Pain is most commonly caused by direct tumor
involvement including ulceration, deep infiltration, early
metastasis, tumor invasion of bone and distension of pain
sensitive structures in soft tissues of the head and neck.3
Tumor invasion of bone is a major cause of pain in all cancer
patients.
The second most common cause of pain is tumor
compression or infiltration of nerve roots trunks or plexuses.
Involvement of mucosal or submucosal nerve endings can
cause burning, uncomfortable dysesthesias and referred pain
like otalgias.3 Facial pain along the distribution of the trigeminal
nerve particularly the mandibular division is common.9
INCIDENCE
Head and neck cancers account for 5 to 10% of all malignant
tumors,1 but are a major cause of morbidity and mortality
in these patients. After excluding lip and larynx cancers,
only 35% of head and neck malignancies are cured.2 Even
non fatal, head and neck cancers have a devastating impact
on patient’s lives as both disease and treatment can affect
the ability to speak, swallow and breathe.
Pain is one of the most feared consequences of
carcinoma3,4 and is experienced by up to 80% of patients
with head and neck carcinoma (HNC).5,6 One of the patients
who was dying of cancer stated, “I found that when I didn”t
have pain I could forget that I had cancer”7 While patients
may be able to ignore enlarged nodes, coughing, hoarseness,
painless lumps or lesions, tumor related pain often drives
them to seek treatment. The incidence of pain as a presenting
symptom in patients having tumors of the oral cavity is
cited at 20%. Pain gets further exacerbated during treatments
like surgery and chemotherapy and most patients with
advanced HNC deal with pain on a daily basis which has a
huge impact on their quality of life.
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Finally pain can occur as a consequence of various
treatment modalities such as surgery, radiotherapy or
chemotherapy.
TYPES OF HNC PAIN
Cancer related pain can be classified into two main types,
nociceptive and neuropathic.
Nociceptive pain is usually well localized and described
as dull, sharp, aching or throbbing. It is caused by acute
tissue injury or by noxious mechanical, thermal or chemical
stimuli. This leads to sensitization of peripheral nociceptors
which are free nerve endings of the A-delta and C-fibers.
Tissue injury leads to inflammation which leads to local
release of “inflammatory soup” which consists of
bradykinin, prostaglandins, substance P, serotonin and other
inflammatory mediators and leads to further sensitization
of peripheral nociceptors. These pain impulses generated
peripherally are transmitted to the dorsal horn of the spinal
cord via the A-delta and C-fibers, and then further centrally.
Nociceptive pain usually responds to NSAIDS
(prostaglandins)10 and opioids (C-fiber related pain).
Neuropathic pain may be described as burning, stabbing,
shooting, electric shock like and may be associated with
local color and temperature changes.
The International Association of Study of Pain (IASP)
defined neuropathic pain as “pain caused by a lesion or
dysfunction of the nervous system.”11
In cases of cancer this may be due to nerve compression
or invasion of the nerve by the tumor. Regeneration of nerves
after damage can lead to neuroma formation and
uncontrolled neuronal firing which may be mediated through
increased expression of both sodium and voltage-gated
calcium channels. Neuropathy generates a local accumula-
tion of sodium channels, with a consequent increase of
density. This remodelling appears to be the basis of neuronal
hyperexcitability.12 Calcium channel expression in the spinal
cord leads to increased release of glutamate which is an
excitatory neurotransmitter. Hence these channels are the
targets for drugs in order to alter expression of neuropathic
pain.
Pain can also be classified as acute, intermittent or
chronic.
Chronic pain is the most common type of pain in HNC
patients and can lead to the associated symptoms of disturbed
sleep, decreased appetite, impaired concentration and
irritability leading to physical deterioration, emotional and
behavioral change.2
EVALUATION OF PAIN IN PATIENTS' WITH HNC
Pain is a subjective phenomenon which requires assessment.
A thorough assessment of the patient's pain is essential to
establish the cause and type of pain before planning its
treatment. Additionally, regular assessment on self reporting
of new pain acts as a trigger for changing therapy or
introducing interventions as required.
A thorough history and physical examination in the
context of the known or suspected primary or secondary
site of tumor including an assessment of the patients
psychosocial status is required to establish a clinical
diagnosis of pain.
History provides valuable information:
• Site: Corresponds to injured area or shows referred pain.
• Onset and pattern of the pain: Classifies pain as acute,
intermittent, chronic or incident.
• Description of the pain: Differentiates nociceptive from
neuropathic pain.
• Severity: Denotes effectiveness of pain treatments.
• Aggravating or relieving factors: Supports selection and
evaluation of analgesic regimen.
• Previous treatments: Inadequate relief from previous
treatment may indicate incorrect diagnosis, disease
progression or treatment failure.
• Psychological and social assessment: Supports holistic
approach to pain management.
Physical examination involves inspection of skin, oral
cavity, paranasal sinuses, larynx and thyroid gland.
Questionnaires like brief pain inventory (BPI) and hospital
anxiety and depression scale (HADS) are useful tools as
they provide an objective analysis of the patients pain and
hence a baseline for further treatment. Additionally, the Leeds
assessment of neuropathic signs and symptoms (LANSS)
questionnaire is useful for identification of neuropathic pain
in these patients.
TREATMENT OF HNC PAIN
The goal of cancer pain treatment is to relieve pain by
modifying its source, interrupting transmission or modulating
its influence on the brain. Pain in HNC patients is multi-
factorial and hence requires a comprehensive and multimodal
approach. This can be achieved by a combination of
treatment modalities (Table 1).
Antineoplastic Therapies
Decreasing tumor burden by primary antineoplastic therapies
remains paramount in the treatment of pain in HNC patients.
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The three main types of treatment for managing head and
neck cancer are radiation therapy, surgery and
chemotherapy. The primary treatments are radiation therapy
or surgery, or both combined; chemotherapy is often used
as an additional, or adjuvant, treatment. As discussed
previously these antineoplastic therapies almost always lead
to pain themselves which will require further management.
Surgery especially if it involves the larynx, mouth and tongue
can be mutilating and may require the reconstruction with
‘flaps’ including forearm and lower limb grafts.13
Pharmacological Therapy
Pharmacological therapy is the foundation of cancer pain
control. Eighty to ninety percent of cases of cancer pain
can be adequately managed through the conceptual analgesic
ladder (World Health Organisation, Geneva, 1986) (Fig. 1)
which recommends that nonopioid or NSAIDS should be
used first and followed, if needed by opioids complemented
by analgesic adjuvants. The conceptual analgesic ladder is
simple to use, well-validated and effective for cancer pain
in general and head and neck cancer in particular.8
Non-narcotic Analgesics
Non-narcotic analgesics are the first line agents for the
management of mild to moderate cancer pain and in severe
pain potentiate the analgesic effects of narcotic analgesics.3
NSAIDS, unless contraindicated, are recommended as the
first step on the conceptual pain ladder. These drugs provide
analgesia by inhibiting the formation of prostaglandins which
are known to sensitize peripheral nociceptors and may play
a role in the central nervous system processing of pain
signals.14 There is evidence to suggest that these medications
have a unique role in managing pain from bony metastasis.15
Non-narcotic analgesics have a ceiling effect and their long-
term use is limited by gastrointestinal and hematological
side effects. Acetaminophen may be considered a NSAID
although it has primarily central effects. Evidence for the
relative efficacy of analgesics can be obtained from the
Oxford league table of analgesics in acute pain.10 The choice
and use of NSAIDS should be individualized with the patient
receiving maximum doses of one drug before another is
tried. If pain control is ineffective or non-narcotic agents
are poorly tolerated then the use of narcotic analgesics is
indicated.
Narcotic Analgesics
Opioid analgesics are the cornerstone of pharmacological
therapy and occupy the remaining rungs of the conceptual
pain ladder. As per the WHO pain ladder, if pain persists
after initial treatment with non opioids, or if at presentation
is moderate to severe opioids should be introduced. Initially
weak opioids such as codeine or tramadol should be
prescribed alone or in combination with acetaminophen. If
maximum dosages are reached weak opioids are rotated to
strong opioids, which include morphine, oxycodone,
hydromorphone, fentanyl and methadone. Although
meperidine is a strong opioid it is not used for cancer pain
due to concerns regarding accumulation of normeperidine
and lowering of seizure threshold.16
Head and neck cancer patients have unique pain
management problems. Involvement of the aerodigestive
tract by disease or treatment often renders the oral route
unavailable and hence versatility of the routes of
TABLE 1: Pain management options in head and neck cancer
Antineoplastic treatment
• Surgery
• Radiotherapy
• Chemotherapy
Pharmacological management
• NSAIDS
• Opioid's
• Adjuvant analgesics
Interventional pain management
Behavioral pain management techniques
Physical therapies (aromatherapy, TENS, relaxation, hypnosis,
acupuncture)
Home based and hospice care
FIGURE 1: WHO pain ladder
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administration of opioids, coupled with lack of ceiling effects
and predictable and manageable side effects makes them
the most important analgesics available to the treating
physician.
Opioids in Management of Acute Head and Neck
Cancer Pain
Head and neck cancer patients frequently have acute pain
which may be the presenting complaint, or related to
antineoplastic therapy. In addition acute pain may be a sign
of recurrence of cancer.
Guidelines for management of pain in the postoperative
period have been published.17 The intravenous route is
preferred until oral route can be established. A starting dose
of morphine is 5-10 mg every 3-4 hours is recommended
for adults weighing >111 pounds. A patient controlled
analgesia device is useful in the postoperative period.18
Patients who are managed by radiation or chemotherapy
may have changing pain and require narcotics for optimal
control of pain.
Opioids in Management of Chronic
Cancer Patients
There are important differences in managing acute pain and
chronic cancer pain primarily due to altered pharmaco-
dynamics due to drug tolerance. Chronic cancer patients
who have been taking opioids for more than a few weeks
are considered opioid tolerant. In the past, there were
concerns regarding addiction with the long-term use of
opioids in cancer patients. However, studies with patterns
of opioid use in cancer patients and other medical illnesses
demonstrate that tolerance and physical dependence occur
but psychological dependence (addiction) is rare.19,20
The principles of use of opioids in cancer pain and as
recommended by WHO (1996) are listed in Table 2.
Opioids via oral route: Opioid analgesics should be given
at fixed intervals for best results. This provides more
continuous pain relief as patients stay within their therapeutic
window. Most short acting opioids have a half life of 3 to 4
hours when given orally and a dose should be given round
the clock, 4 hourly.21 However ‘Breakthrough pain’, i.e.
pain experienced despite round the clock analgesia, may
occur despite regular opioid dosing and typically the same
opioid is used for regular and breakthrough pain. When
initiating an opioid, the breakthrough dose is calculated at
least half of the routine 4 hourly dose or 10 to 20% of the
total daily dose of opioid.22 If multiple doses are required
for breakthrough pain, several days in a succession, the
round the clock dose should be increased by the amount of
opioid given in rescue doses in 24 hours.18 If pain stabilizes
on a short acting opioid, the long acting equivalent may be
substituted. The availability of breakthrough doses does not
change.
Other routes of opioid administration: Wherever
possible, opioids should be administered by mouth which is
the least invasive and least expensive route. Wherever oral
route is not available as in advanced HNC, rectal or
transdermal route may be used. The mechanism of action
of the transdermal opioids available (Fentanyl and
Buprenorphine) is that low molecular weight lipophilic
molecules contained in a drug reservoir, migrate across the
skin into the capillary blood stream because of a
concentration gradient.
Skaer et al (2006) suggests an algorithm using the
equivalence between 60 mg/day morphine and a 25 µg/hr
patch of fentanyl with titration upwards at 24 hours if
required.23 Pain relief from a fentanyl patch begins 8 to 12
hours after application and oral opiates should be utilized
for pain control during the transition period. The patch needs
to be changed every 72 hours. The elimination half life is
12 to 22 hours once a patch is removed. Oral transmucosal
fentanyl citrate (OTFC) (introduced 1998) or Fentanyl buccal
tablets (FBT) (introduced 2006) may be used for
management of breakthrough pain.24
Transdermal buprenorphine may also be used for
management of cancer pain with oral morphine used for
breakthrough pain.
Opioid use is limited by their side effects-respiratory
depression, sedation, pruritis, nausea and vomiting, urinary
retention and constipation. The occurrence of these side
effects should be anticipated and treated. Most of these
side effects except sedation and constipation decrease with
time. A stool softener and laxative should always be
TABLE 2: Principles of opioid use in cancer patients
By the mouth
By the clock
By the ladder
For the individual
Attention to detail
Data from World Health Organization, Cancer Pain Relief (ed 2),
1996.
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prescribed with initiation of opioid therapy.14 At any stage a
non opioid may be prescribed to potentiate the effect of the
opioid and hence decrease the dose to avoid side effects.
Adjuvant Analgesics
A number of other classes of drugs can be used to enhance
the effect of narcotic and non-narcotic medication. These
include antidepressants, anticonvulsants, local anesthetic
plasters and steroids as the most common ones.
Drugs used for neuropathic pain: The neuropathic
component of cancer pain is frequently underdiagnosed or
inadequately treated or both. Patients may describe the pain
as burning, shooting stabbing, radiating or aching in the
dermatomal distribution of the damaged neural structure.
Although used widely in cancer pain opioids may have limited
efficacy in the management of neuropathic pain.25-27
Finnerup et al in 2005 formulated a treatment algorithm
for neuropathic pain on the basis of a review of 105 high-
quality, randomized, placebo-controlled clinical trials. They
concluded TCAs had the lowest numbers needed to treat
(NNT) followed by opioids and antiepileptic drugs such as
gabapentin and pregabalin.28
Amitryptyline (Tricyclic antidepressant) can produce
direct analgesic effect through blocking serotonin and
noradrenalin reuptake at CNS synapses. It can be started at
a dose of 10 to 25 mg at bedtime and increased to 50 to
150 mg at bedtime. Its use is limited by sedative and
anticholinergic side effects (dry mouth, urinary retention,
delirium).
Gabapentin is an anticonvulsant drug licensed for use in
neuropathic pain. It acts centrally at dorsal horn neurons
by binding to calcium channels. Gabapentin is usually started
a low dose and then titrated upwards, as necessary to achieve
pain relief and as tolerated be the patient. It is usually
prescribed to be taken three times a day. Gabapentin is
excreted unchanged by the kidneys and hence dosage
adjustments are required in patients with renal failure. Data
from a recent (2007) randomized trial on cancer patients
with neuropathic pain, suggests that gabapentin added to
an opioid provides better relief of neuropathic pain in cancer
patients than opioid monotherapy.29
Pregabalin is an anticonvulsant similar in structure to
gabapentin which was designed to have greater affinity for
the same calcium channels blocked by gabapentin. The linear
pharmacokinetics of pregabalin allow for twice daily dosing
and rapid titration as compared to gabapentin.30
Corticosteroids possess analgesic properties for several
cancer pain syndromes including both neuropathic and bone
pain.31 The risk of adverse effects increases with dose and
duration of therapy.
INTERVENTIONAL PAIN MANAGEMENT
Among the head and neck cancer patients, 10 to 20% do
not obtain satisfactory pain relief or get unacceptable side
effects from systemic pharmacological therapy. It is in this
group of patients that invasive techniques such as nerve
blocks, neurodestructive procedures and intraspinal/
intrathecal drug infusions may be indicated.14
Cranial and peripheral nerves which may be commonly
blocked either centrally or peripherally are trigeminal,
glossopharyngeal, occipital, vagus and branches of the
cervical plexus.14 However, sensory innervations may
overlap due to anatomic distortion due to cancer, surgery
or radiotherapy. Occipital nerve block is the treatment for
the symptomatic management of occipital headaches which
may be the manifestation of base of skull invasion by cancer.
Myofacial pain may be present in the area of trapezius or
the sternocleidomastoid which may respond to trigger point
injections. Pain in the C2, C3 dermatomal distribution
following radical neck dissection may be alleviated by
superficial cervical plexus block.
A 3-stage process involving diagnostic, prognostic, and
therapeutic blocks is recommended to ensure appropriate
patient selection and therapeutic efficacy.32 Diagnostic nerve
blocks identify the anatomic source of pain and are best
performed using relatively short-acting local anesthetics
such as lidocaine 1% or 2%. Prognostic nerve blocks give
patients the opportunity to experience the numbness and
other side effects associated with regional blocks in the
head and neck.
Injection of a long-acting local anesthetic, such as
bupivacaine, enables the patient to feel the sensation of
“numbness” that will be associated with the subsequent
neurolysis. Local anesthetic blocks can be useful in
prognosticating the results of the intended neurolytic block
and subsequently, alcohol or phenol may be used for
neurolysis.32
Chemical or radiofrequency neurolysis has been used
for lesions involving trigeminal ganglion and its branches,
glossopharyngeal nerve and sphenopalatine ganglion.
Varghese et al described a technique of nasal endoscopically
guided neurolytic sphenopalatine ganglion block with 6%
phenol after a prognostic block with local anesthetic solution.
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They performed the block in 22 patients with advanced
head and neck malignancy and reported good pain relief in
17 patients and inadequate relief in one patient only.33
Therefore in well-selected patients with intractable pain
neurosurgical destructive procedures such as dorsal
rhizotomy or trigeminal tractotomy may have a role.
However, these procedures are invasive and have associated
morbidity and mortality. The pain relief obtained is often
temporary and linked with side effects like sensory and
motor dysfunction. Neurosurgical procedures may be
technically difficult and pain relief may not occur at all or
pain may return after a variable period of time. Following
surgery there may be also be nerve and tract regeneration
and somatotopographic reorganization including opening of
alternate pathways.34 Therefore these procedures are not
commonly performed currently.11
Intrathecal morphine may be used by infusion via
implantable delivery systems after a diagnostic trial, to
determine pain relief in cases with intractable pain. Sites
caudal to the cervical region may cause analgesia in the
cervical or cranial regions.14 Applegren et al (1996) reported
the use of intracisternal and high cervical intrathecal
bupivacaine infusion in refractory head and neck pain with
very few complications.35 However, these treatments are
invasive and more experience is needed before such
treatments are commonly used in head and neck cancer
patients.
Alternative Therapy
Behavioural Management Techniques
The aim of behavioral management approaches is to help
the patient regain a sense of control which has been
undermined by disease and debility.
Behavioral approaches including cognitive behavioral
training, hypnosis, reiki biofeedback and relaxation therapies
have been used. These techniques serve as a calming
diversion of attention breaking the pain-anxiety-tension
cycle.
Physical Modalities
Physical modalities such as TENS and acupuncture may be
used in conjunction with other management approaches. A
recent randomized control trial (2008) by P fister et al on
70 patients postradical neck dissection for HNC, showed
acupuncture to provide pain relief in 39% patients compared
to 7% standard care group.36
CONCLUSION
Pain is the one of the most feared complications of advancing
cancer. In addition the effect is probably magnified in the
head and neck cancer patient due to the additional burden
of pain on functionality and cosmesis. Assessment of the
type and cause of pain in these patients helps clinicians to
define proper therapy. The analgesic ladder provides an
effective framework which can be modified to suit the needs
of particular patients. An understanding of pain pathways
and mechanisms allows for addition of adjuvant drugs,
interventional treatments and physical and psychological
treatments for overall management and compassionate
treatment of this subgroup of patients. In conclusion,
“Cancer pain should be treated as aggressively as the cancer
itself.”
REFERENCES
1. Keefe FJ, Manuel G, Brantley A. Pain and the head and neck
cancer patient: Changes over treatment. Head Neck Surg
1986;8:169-76.
2. Raj PP, Phero JC. Pain control in cancer of the head and neck in
Thawley SE, Panje WR (Eds): Comprehensive management of
Head and Neck Tumors. Philadelphia. PA Saunders. 1987;1:42-
68.
3. Foley KM. The treatment of cancer pain. N Engl J Med
1985;313:84-95.
4. Olsen KD, Creagan ET. Pain management in advanced carcinoma
of the head and neck. Am J Otolaryngol 1991;12:154-69.
5. Lyons MF, Redmond J, Covelli H. Multiple primary neoplasia
of the head and neck and lung: The changing histopathology
Cancer1986;57:2193-97.
6. Foley KM, Intrinsic CE. Analgesic drug therapy in cancer pain:
Principles and practice. Med Clin North Am 1987;71:207-32.
7. McGivney WT, Crooks GM. The care of patients with severe
chronic pain in terminal illness. JAMA 1984;251:1182-88.
8. Grond S, Zech D, Lynch J, Diefenbach C, Schug SA, Lehmann
KA. Validation of World Health Organisation Guidelines for
pain relief in head and neck cancer. A prospective study. Ann
Otol Rhinol Laryngol 1993;102:342-48.
9. Shapshay SM, Scott RM, McCann CF, Stoelting I. Pain control
in advanced and recurrent head and neck cancer. Otolaryngol
Clin North Am 1980;13:551-60.
10. Oxford league table of analgesics in acute pain. Bandolier 2007
[Accessed:26/11/2009] Available from http://
www.medicine.ox.ac.uk/bandolier/booth/painpag/Acutrev/
Analgesics/Leagtab.html.
11. “Part III: Pain Terms, A Current List with Definitions and Notes
on Usage” Classification of Chronic Pain, Second Edition, IASP
Task Force on Taxonomy, edited by H. Merskey and N. Bogduk,
IASP Press, Seattle, © 1994;209-14.
12. Aurilio C, Pota C, Pace MC, Passavanti MB, Barbarisi M. Ionic
channels and neuropathic pain: Physiopathology and applications.
J of cellular physio 2008;215(1):8-15.
Pain Management in Patients with Head and Neck Carcinoma
Otorhinolaryngology Clinics: An International Journal, January-April 2010;2(1):69-75 75
13. Head and neck cancer. In: Lecture notes: Diseases of Ear Nose
Throat. Bull P, Clarke R editors (10th ed). Wiley-Blackwell
2007;142-46.
14. Dennis J, Patin MD. Pain control in head and neck cancer. Current
opinion in otolaryngology and head and neck surgery 1998;86:85-
89.
15. Brodie GN. Indomethacin and bone pain. Lancet 1974;2:1160.
16. Inturrisi CE. Clinical pharmacology of opioids for pain. Clin J of
Pain 2002;18(suppl):S3-13.
17. Carr DB, Jaycox A. Acute pain management in adults: Operative
procedures. Agency for health care policy and research. US
department of health and human services 1992.
18. Thompson AR. Opioids and their proper use as analgesics in
the management of head and neck cancer patients. Am J of
Otolaryngol 2000;21(4):244-54.
19. Angell M. The quality of mercy. N Eng J Med 1982;306:98-99.
20. Porter J, Hick H. Addiction rare in patients treated with narcotics.
N Eng J Med 1980;302:123.
21. MacDonald N. Palliative Medicine: A Case Based Manual (2nd
ed). New York: Oxford University Press; 1998.
22. Bruera E, Kim HN. Cancer Pain. JAMA 2003;290:2476-79.
23. Skaer TL. Transdermal opioids for cancer pain. Health qual life
outcomes 2006;4:24.
24. Darwish M, Messina J. Clinical pharmacology of fentanyl buccal
tablet for the treatment of breakthrough pain. Expert rev clin
pharmacol 2008;1(1):39-47.
25. Dellemijn P. Are opioids effective in relieving neuropathic pain?
Pain 1999;80:453-62.
26. Katz N, Benoit C. Opioids for neuropathic pain. Curr Pain
Headache Rep 2005;9:153-60.
27. Arner S, Mayerson BA. Lack of analgesic effect of opioids on
neuropathic and idiopathic forms of pain. Pain 1988;33:11-23.
28. Finnerup NB, Otto M, Jenson TS, et al. Algorithm for
neuropathic pain treatment: An evidence based proposal. Pain
2005;118:289-305.
29. Keskinbora K, Pelek AF, Aydinli I. Gabapentin plus opioid for
managing neuropathic cancer pain. J Pain Symptom Manage
2007;34(2):183-89.
30. Ben-Menachem E. Pregabalin pharmacology and its relevance to
clinical practice. Epilepsia 2004;45(6):13-18.
31. Portenoy RK. Adjuvant analgesics in pain management. In: Doyle
D, Hanks GWC, MacDonald N (Eds). Oxford Textbook of
Palliative Medicine (2nd ed). New York, NY. Oxford University
Press 1998.
32. Sist T. Head and neck nerve blocks for cancer pain management.
Tech Reg Anesth Pain Manage 1997;1:3-10.
33. Varghese BT, Koshy RC. Endoscopic transnasal neurolytic
sphenopalatine ganglion block for head and neck cancer pain. J
Laryngol and Otol 2001;115(5):385-87.
34. Tasker RR. The recurrence of pain after neurosurgical procedures.
Qual of life research 1994;3(1):S43-49.
35. Appelgren L, Janson M, Nitescu P, Curelaru L. Continuous
intracisternal and high cervical intrathecal bupivacaine analgesia
in refractory head and neck pain. Anaesthesiology 1996;84:256-
72.
36. Press release. Acupuncture reduces pain and dysfunction in
head and neck cancer patients after neck dissection. 31Mar 2008.
(Accessed 19 Nov 2009). Available from: http://www.mskcc.org/
mskcc/html/85411.cfm.
